Xiuyi Zhi

Xiuyizhi is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology and other serious diseases. The company leverages a proprietary structure-based drug design platform to target "undruggable" proteins, with a particular focus on epigenetic regulators and protein-protein interactions. Its lead candidate, SYZ-8001, is a potent and selective CBP/p300 inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors and hematological malignancies. Xiuyizhi aims to address significant unmet medical needs by developing first-in-class or best-in-class medicines through deep expertise in medicinal chemistry and structural biology. The company is supported by leading venture capital investors, including Qiming Venture Partners and Matrix Partners China.